<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To report a single case of <z:chebi fb="0" ids="16704">uridine</z:chebi> glucuronosyltransferase 1A1 (UGT1A1) polymorphism and <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> in a patient who received <z:chebi fb="0" ids="50924">sorafenib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A 63-year-old man with <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> was diagnosed with <z:hpo ids='HP_0001402'>hepatocellular carcinoma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>His <z:hpo ids='HP_0001394'>cirrhosis</z:hpo> was categorized as Child-Pugh A, total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration was 24 micromol/L (<z:mpath ids='MPATH_458'>normal</z:mpath> range &lt;20 micromol/L) </plain></SENT>
<SENT sid="3" pm="."><plain>The patient was enrolled in a phase I trial combination study of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> combined with <z:chebi fb="0" ids="50924">sorafenib</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: After a single infusion of <z:chebi fb="0" ids="28748">doxorubicin</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> and 7 days of <z:chebi fb="0" ids="50924">sorafenib</z:chebi>, he presented with an elevated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> concentration (48 micromol/L) </plain></SENT>
<SENT sid="5" pm="."><plain>Unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> was 38 micromol/L and conjugated was 10 micromol/L </plain></SENT>
<SENT sid="6" pm="."><plain>The patient was found to have one mutant allele (UGT1A1*28) </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The isolated increase in serum <z:chebi fb="0" ids="16990">bilirubin</z:chebi> levels in our patient was probably due to <z:chebi fb="0" ids="50924">sorafenib</z:chebi>-induced UGT1A1 inhibition that manifested itself due both to the patient having one UGT1A1*28 allele and the presence of underlying <z:e sem="disease" ids="C0023895" disease_type="Disease or Syndrome" abbrv="">liver disease</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="16990">Bilirubin</z:chebi> elevations in patients treated with <z:chebi fb="0" ids="50924">sorafenib</z:chebi> could indicate progression or drug toxicity; hence, these possibilities need to be ruled out </plain></SENT>
<SENT sid="9" pm="."><plain>We would suggest that when patients develop <z:hpo ids='HP_0002904'>hyperbilirubinemia</z:hpo> while taking <z:chebi fb="0" ids="50924">sorafenib</z:chebi> for any indication, consideration be given to obtaining a fractionation of <z:chebi fb="0" ids="16990">bilirubin</z:chebi> and consideration of UGT1A1 genotyping in order to exclude a <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> as possible reason for the hyperbilrubinemia </plain></SENT>
<SENT sid="10" pm="."><plain>Further studies are warranted to analyze the impact of <z:chebi fb="0" ids="50924">sorafenib</z:chebi> treatment on unconjugated <z:chebi fb="0" ids="16990">bilirubin</z:chebi> blood levels in patients with <z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert's syndrome</z:e> </plain></SENT>
</text></document>